Hims Stock Hits New ATH

Hims & Hers Stock Soars on Momentum From Super Bowl Ad, RFK Confirmation
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday as the company’s [controversial Super Bowl ad](
HIMS Stock Hits New ATH After Successful Super Bowl Ad
Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth company. A
Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. | Hims & Hers hit the bullseye with its Super Bowl ad,
Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry.
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk (NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's
Why Hims & Hers Health Inc. (HIMS) Went Up on Thursday
We recently published a list of 10 Firms Post Double-Digit Gains on Thursday. In this article, we are going to take a look at ...
What Is Hims Actually Selling?
The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Money Morning3d
HIMS Stock Surge: Is There Still Time to Buy Hims & Hers?
Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hosted on MSN2d
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $60.30, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%. On ...